These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 33823761)

  • 21. Feeding Next-Generation Nanomedicines to Europe: Regulatory and Quality Challenges.
    Musazzi UM; Franzè S; Condorelli F; Minghetti P; Caliceti P
    Adv Healthc Mater; 2023 Dec; 12(30):e2301956. PubMed ID: 37718353
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bringing nanomedicines to market: regulatory challenges, opportunities, and uncertainties.
    Nijhara R; Balakrishnan K
    Nanomedicine; 2006 Jun; 2(2):127-36. PubMed ID: 17292125
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Summary of the EMA Joint Regulators/Industry QbD workshop (London, UK; 28-29 January 2014).
    Cook G; France G; Holte Ø; Lorenti G; Tainsh D
    PDA J Pharm Sci Technol; 2016; 70(2):163-76. PubMed ID: 26797977
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulatory aspects on nanomedicines.
    Sainz V; Conniot J; Matos AI; Peres C; Zupancic E; Moura L; Silva LC; Florindo HF; Gaspar RS
    Biochem Biophys Res Commun; 2015 Dec; 468(3):504-10. PubMed ID: 26260323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulating nanomedicine - can the FDA handle it?
    Bawa R
    Curr Drug Deliv; 2011 May; 8(3):227-34. PubMed ID: 21291376
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bridging communities in the field of nanomedicine.
    Halamoda-Kenzaoui B; Baconnier S; Bastogne T; Bazile D; Boisseau P; Borchard G; Borgos SE; Calzolai L; Cederbrant K; Di Felice G; Di Francesco T; Dobrovolskaia MA; Gaspar R; Gracia B; Hackley VA; Leyens L; Liptrott N; Park M; Patri A; Roebben G; Roesslein M; Thürmer R; Urbán P; Zuang V; Bremer-Hoffmann S
    Regul Toxicol Pharmacol; 2019 Aug; 106():187-196. PubMed ID: 31051191
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of Pharmaceutical Nanomedicines: From the Bench to the Market.
    Halwani AA
    Pharmaceutics; 2022 Jan; 14(1):. PubMed ID: 35057002
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quality by Design Approach in Liposomal Formulations: Robust Product Development.
    Alshaer W; Nsairat H; Lafi Z; Hourani OM; Al-Kadash A; Esawi E; Alkilany AM
    Molecules; 2022 Dec; 28(1):. PubMed ID: 36615205
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Updated Regulatory Considerations for Nanomedicines.
    Subin TS; Vijayan V; Kumar KJR
    Pharm Nanotechnol; 2017; 5(3):180-191. PubMed ID: 28641516
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comprehensive insights into mechanism of nanotoxicity, assessment methods and regulatory challenges of nanomedicines.
    Havelikar U; Ghorpade KB; Kumar A; Patel A; Singh M; Banjare N; Gupta PN
    Discov Nano; 2024 Oct; 19(1):165. PubMed ID: 39365367
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combining Nanomedicine and Immunotherapy.
    Shi Y; Lammers T
    Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quality-by-design-based engineered liposomal nanomedicines to treat cancer: an in-depth analysis.
    Kapoor D; Sharma S; Verma K; Bisht A; Sharma M; Singhai NJ; Raval N; Maheshwari R
    Nanomedicine (Lond); 2022 Jul; 17(17):1173-1189. PubMed ID: 36178357
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Methodological Safe-by-Design Approach for the Development of Nanomedicines.
    Schmutz M; Borges O; Jesus S; Borchard G; Perale G; Zinn M; Sips ÄAJAM; Soeteman-Hernandez LG; Wick P; Som C
    Front Bioeng Biotechnol; 2020; 8():258. PubMed ID: 32300587
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nanomedicines accessible in the market for clinical interventions.
    Gadekar V; Borade Y; Kannaujia S; Rajpoot K; Anup N; Tambe V; Kalia K; Tekade RK
    J Control Release; 2021 Feb; 330():372-397. PubMed ID: 33370576
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transforming nanomedicine manufacturing toward Quality by Design and microfluidics.
    Colombo S; Beck-Broichsitter M; Bøtker JP; Malmsten M; Rantanen J; Bohr A
    Adv Drug Deliv Rev; 2018 Mar; 128():115-131. PubMed ID: 29626549
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nanomedicine-based commercial formulations: current developments and future prospects.
    Thapa RK; Kim JO
    J Pharm Investig; 2023; 53(1):19-33. PubMed ID: 36568502
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preclinical hazard evaluation strategy for nanomedicines.
    Siegrist S; Cörek E; Detampel P; Sandström J; Wick P; Huwyler J
    Nanotoxicology; 2019 Feb; 13(1):73-99. PubMed ID: 30182784
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overview of the blood compatibility of nanomedicines: A trend analysis of in vitro and in vivo studies.
    Urbán P; Liptrott NJ; Bremer S
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 May; 11(3):e1546. PubMed ID: 30556649
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mapping of the available standards against the regulatory needs for nanomedicines.
    Halamoda-Kenzaoui B; Holzwarth U; Roebben G; Bogni A; Bremer-Hoffmann S
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Jan; 11(1):e1531. PubMed ID: 29923692
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of nanomedicines: A reflection on a field under construction needed for clinical translation success.
    Coty JB; Vauthier C
    J Control Release; 2018 Apr; 275():254-268. PubMed ID: 29454063
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.